Abstract
Bosentan, a dual endothelin receptor antagonist, may reduce blood pressure by blocking the vasoconstrictor effect of endothelin-1. In systemic sclerosis (SSc) nailfold videocapillaroscopy (NVC); allows diagnostic and follow-up of microvascular damage. Distinct NVC patterns have been identified for the evaluation of severity of SSc microvascular damage. The objective of this study is to evaluate the modification of the microvasculature under Bosentan therapy in SSc patients with pulmonary arterial hypertension (PAH). Nine patients with PAH related to SSc in New York Heart Association classes III–IV were treated with Bosentan 125 mg twice a day. NVC optical probe videocapillaroscopy equipped with 100× and 200× contact lenses and connected to image analyse software was performed before and after 12 months of Bosentan therapy to evaluate the modification of microvasculature. Nine PAH SSc patients treated with Iloprost were used as controls. Before Bosentan therapy, seven patients showed at NVC severe loss of capillaries with large avascular areas and vascular architectural disorganisation which are typically “late” SSc pattern. After 12 months of Bosentan, NVC pattern changed in seven patients from “late” into “active” SSc pattern. The disappearance of avascular areas and capillary haemorrhages was the most striking result. Two patients had an “active” SSc pattern, not modified by Bosentan treatment. These data show that Bosentan may improve NVC pattern in SSC and the presence of new capillaries suggests that it may favour angiogenesis. Bosentan may improve and stabilise the microvasculature in long-term treatment modulating the structural modifications detected by NVC.
Similar content being viewed by others
References
Guiducci S, Giacomelli R, Matucci Cerinic M (2007) Vascular complications of scleroderma. Autoimmun Rev 6:520–523
Cutolo M, Grassi W, Matucci Cerinic M (2003) Raynaud’s phenomenon and the role of capillaroscopy. Arthritis Rheum 48:3023–3030
Maricq HR (1981) Widefield capillary microscopy: technique and rating scale for abnormalities seen in scleroderma and related disorders. Arthritis Rheum 24:1159–1165
Yanagisawa M, Kurihara H, Kimura S, Tombe Y, Kobayashi M, Mitsui Y et al (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411–415
Ramirez A, Varga J (2004) Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management. Treat Respir Med 3:339–352
Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E et al (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985–3993
LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205
Caramaschi P, Martinelli N, Volpe A, Pieropan S, Tinazzi I, Patuzzo G et al (2009) A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost. Clin Rheumatol 28:807–813
Cutolo M, Pizzorni C, Sulli A (2000) Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 27:155–160
Miniati I, Guiducci S, Conforti ML, Rogai V, Fiori G, Cinelli M et al (2009) Autologous stem cell transplantation improves microcirculation in systemic sclerosis. Ann Rheum Dis 68:94–98
Aschwanden M, Daikeler T, Jaeger KA, Thalhammer C, Gratwohl A, Matucci-Cerinic M et al (2008) Rapid improvement of nailfold capillaroscopy after intense immunosuppression for systemic sclerosis and mixed connective tissue disease. Ann Rheum Dis 67:1057–1059
Disclosures
None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Guiducci, S., Bellando Randone, S., Bruni, C. et al. Bosentan fosters microvascular de-remodelling in systemic sclerosis. Clin Rheumatol 31, 1723–1725 (2012). https://doi.org/10.1007/s10067-012-2074-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-012-2074-5